Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00950 LEE'S PHARM
RTNominal down1.190 -0.020 (-1.653%)
Others

23/07/2021 09:35

Lee's Pharm (00950) enrols first patient in trial phase III

[ET Net News Agency, 23 July 2021] Lee's Pharmaceutical Holdings Limited (00950) said
China Oncology Focus Limited (COF), a subsidiary of the company, has enrolled the first
patient in China in the Phase III, multicentre, randomised, double blinded, placebo
control clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as
ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage
small-cell lung cancer (ESSCLC). The clinical trial approval was granted by China's
National Medical Products Administration (NMPA) on 1 March 2021.
The initiation of this Phase III trial is based on the results from an earlier Phase Ib
trial in which Socazolimab combined with carboplatin and etoposide showed promising
efficacy and safety profile in patients with ES-SCLC. This clinical trial involves 56
centres and is led by Prof. Shun Lu from Shanghai Chest Hospital. (RC)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.